Two patients with the same type of cancer can respond very differently to the same treatment. Part of the reason lies in the tumour's surroundings, including the immune system, and that biology is hard to capture before treatment begins. Solid IO, based in Helsinki, is building a tumour-on-chip platform that tests how living patient tissue responds to cancer therapies. We spoke with Noora Hujala, CEO and Co-Founder, about the technology, its use in pharma and biotech research, and the company's first clinical feasibility study.
Why treatment response is hard to predict
Understanding how a tumour will respond to a therapy is one of the biggest challenges in oncology. Common gaps include:
Tumour response depends on surrounding biology, including immune cells, which simpler models can leave out
Responses vary from patient to patient, even within the same cancer type
Profiling data shows what is present in a tumour, but not always what happens when it is exposed to a drug
Immunotherapies, antibody-drug conjugates and combination treatments add more variables to test
For drug developers, this makes it harder to see which patients a therapy is likely to help. For clinicians, it means treatment decisions often rely on population-level evidence rather than on how an individual tumour behaves.
From Harvard and Dana-Farber to Helsinki
Solid IO grew out of research led by scientific co-founder Heidi Haikala. After time at Harvard and Dana-Farber Cancer Institute, she returned to Helsinki and set up her own laboratory.
That research became the basis for Solid IO's approach: measuring treatment response directly in living patient tissue, with the tumour's immune environment kept in the picture.
Noora Hujala leads the company as CEO and Co-Founder. Today, Solid IO combines clinical development work in Helsinki with research services for pharmaceutical and biotech companies.
What sets Solid IO apart?
Built on the patient's own tissue. The platform uses patient-derived material, so researchers can study treatment response in the context of an individual patient's biology rather than a generic model.
The immune system is part of the model. By representing interactions between cancer and immune cells, the platform can show effects that tumour-only models cannot. This is particularly relevant for immunotherapies.
Functional data, not just a profile. Solid IO asks a direct question: what happens when this tumour model is exposed to a therapy? The answer is a measured response, rather than a prediction based on markers alone.
The platform: patient-specific tumour-on-chip
Solid IO combines patient-derived samples with organ-on-chip technology. Key features include:
Tumour models built from patient-derived material
Modelling of the tumour microenvironment, including immune interactions
Testing across a range of therapies, including immunotherapies, antibody-drug conjugates and combinations
Readouts on immune activation and treatment-specific tumour killing
Several layers of treatment-response data from each sample
In published proof-of-concept work, the team combined patient-derived tumour models with patients' own immune cells, then measured immune activation and tumour killing. When testing anti-PD-1 on its own and in combination, responses differed between patients – the kind of variation the platform is designed to pick up. The platform is currently for research use only.
Supporting pharma and biotech research
Alongside its clinical work, Solid IO offers research services to pharmaceutical and biotech companies. It has announced a collaboration with Ymmunobio, a Swiss oncology biotech, which will use the platform to test how patient-derived tumour tissue responds to an investigational cancer therapy. The aim is to generate functional data that complements Ymmunobio's existing preclinical work.
Why it matters for oncology drug development
Results from preclinical models do not always carry over to patients, and late-stage failures in oncology are costly. Models that reflect individual patient biology, including the immune response, can give teams earlier evidence on which patients and which treatment combinations are worth pursuing.
Solid IO's work forms part of functional precision oncology: testing how living patient-derived material responds when exposed to treatment. The longer-term question is how these observations relate to patient outcomes, and whether they could eventually help inform clinical decisions.
What it means for hiring
Companies in functional precision oncology sit between lab science, clinical research and commercial partnerships. As they move from proof-of-concept into clinical studies and pharma collaborations, they need leaders who have worked across those areas. Senior roles that often become critical at this stage include:
Head of Translational Oncology – links platform data to clinical outcomes and builds the evidence base
Clinical Development or Clinical Operations Lead – runs feasibility studies and manages hospital partnerships
VP Business Development – builds pharma and biotech partnerships and grows research-services revenue
Head of Regulatory & Quality – plans the route from research use only to clinical application
What's next for Solid IO?
The immediate priority is the clinical feasibility study with Helsinki University Hospital, which started in November 2026 at the HUS Comprehensive Cancer Center and focuses on triple-negative breast cancer (TNBC). The study looks at how the workflow performs with fresh patient samples in a clinical setting. At this stage the focus is workflow feasibility, not how accurately the platform predicts patient responses.
Solid IO has also joined Bayer Co.Lab Berlin, giving it access to industry mentorship and pharma and biotech teams, and has been accepted into Creative Destruction Lab Seattle's 2026/27 Computational Health programme, where it will refine its commercial strategy and explore routes to the global market. To learn more about the technology or discuss a collaboration, visit Solid IO's website.
—




